Zhang, Tianzhuo
Yue, Zhijie
Yu, Ling
Li, Shuo
Xie, Yining
Wei, Jin
Wu, Mengge
Liu, Honglei
Tan, Hongyu
Funding for this research was provided by:
Wu Jieping Medical Foundation (320.6750.2021-4-18)
Article History
Received: 22 January 2023
Accepted: 27 March 2023
First Online: 30 March 2023
Declarations
:
: Ethical approval was obtained from the Institutional Review Board at Peking University Cancer Hospital’s Ethics Committee (No.2021YJZ109) address: Peking University Cancer Hospital’s Ethics Committee, No. 81 Fucheng Street, Haidian District, Beijing, China. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2200055180, date of registration: 2022–01-02) prior to patient enrollment. The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. Written informed consent was obtained from all patients.
: Not applicable.
: The authors declare that they have no competing interests.